Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8261043 | 0.91 | KDM4E (0.55) | KDM4ENR3C2GAANR1I2NR3C1 | |
| SCHEMBL8256663 | 0.91 | NR3C2 (0.43) | KDM4ENR3C2GAA | |
| SCHEMBL8261054 | 0.89 | KDM4E (0.54) | KDM4ENR3C2GAA | |
| SCHEMBL8261047 | 0.88 | KDM4E (0.52) | KDM4ENR3C2 | |
| SCHEMBL4379641 | 0.87 | KDM4E (0.54) | KDM4ENR3C2GAANR1I2NR3C1 | |
| SCHEMBL8261045 | 0.84 | KDM4E (0.54) | KDM4ENR3C2 | |
| SCHEMBL8261057 | 0.84 | NR3C2 (0.61) | KDM4ENR3C2 | |
| SCHEMBL13587771 | 0.83 | NR3C2 (0.56) | KDM4ENR3C2 | |
| SCHEMBL8259167 | 0.82 | KDM4E (0.54) | KDM4ENR3C2 | |
| SCHEMBL13587732 | 0.81 | KDM4E (0.53) | KDM4ENR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298872-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | IRM LLC (BM) | 2009-12-03 | — | — | US | disclosed |
| WO-2006066011-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | IRM LLC (BM) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298872-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | TRPV1, TRPV2, TRPV6 | KDM4E 3960/4885NR3C2 12/4885GAA 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.